Recombinant DNA Technology Market Research Report - Forecast to 2032

Recombinant DNA Technology Market Research Report: Information By Product (Medical and Non-Medical), By Component (Expression System and Cloning Vector), By Application (Food & Agriculture, and Health & Disease), By End User (Biotechnology Companies and Pharmaceuticals) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

ID: MRFR/LS/4389-HCR | 100 Pages | Author: Rahul Gotadki | March 2024         

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Recombinant DNA Technology Market, by Product

6.1 Introduction

6.2 Medical

6.2.1 Market Estimates & Forecast, 2020-2027

6.2.2 Therapeutic Agent

6.2.2.1 Market Estimates & Forecast, 2020-2027

6.2.3 Human Protein

6.2.3.1 Market Estimates & Forecast, 2020-2027

6.2.4 Vaccine

6.2.4.1 Market Estimates & Forecast, 2020-2027

6.3 Non-Medical

6.3.1 Market Estimates & Forecast, 2020-2027

6.3.2 Biotech Crops

6.3.2.1 Market Estimates & Forecast, 2020-2027

6.3.3 Specialty Chemicals

6.3.3.1 Market Estimates & Forecast, 2020-2027

6.3.4 Others

6.3.4.1 Market Estimates & Forecast, 2020-2027

6.4 Others

Chapter 7. Global Recombinant DNA Technology Market, by Component

7.1 Introduction

7.2 Expression System

7.2.1 Market Estimates & Forecast, 2020-2027

7.2.2 Mammalian

7.2.2.1 Market Estimates & Forecast, 2020-2027

7.2.3 Bacteria

7.2.3.1 Market Estimates & Forecast, 2020-2027

7.2.4 Yeast

7.2.4.1 Market Estimates & Forecast, 2020-2027

7.2.4 BaculovirU.S./Insect

7.2.4.1 Market Estimates & Forecast, 2020-2027

7.2.5 Others

7.2.5.1 Market Estimates & Forecast, 2020-2027

7.3 Cloning Vector

7.3.1 Market Estimates & Forecast, 2020-2027

7.3.2 Plasmid

7.3.2.1 Market Estimates & Forecast, 2020-2027

7.3.3 Phage

7.3.3.1 Market Estimates & Forecast, 2020-2027

7.3.4 Cosmid

7.3.4.1 Market Estimates & Forecast, 2020-2027

7.3.5 Bacterial Artificial Chromosome (BAC)

7.3.5.1 Market Estimates & Forecast, 2020-2027

7.3.6 Yeast Artificial Chromosome (YAC)

7.3.6.1 Market Estimates & Forecast, 2020-2027

7.3.7 Human Artificial Chromosome (HAC).

7.3.7.1 Market Estimates & Forecast, 2020-2027

7.4 Others

Chapter 8. Global Recombinant DNA Technology Market, by Application

8.1 Introduction

8.2 Food & Agriculture

8.2.1 Market Estimates & Forecast, 2020-2027

8.3 Health & Disease

8.3.1 Market Estimates & Forecast, 2020-2027

8.4 Environment

8.4.1 Market Estimates & Forecast, 2020-2027

8.5 Others

Chapter 9. Global Recombinant DNA Technology Market, by End-U.S.er

9.1 Introduction

9.2 Biotechnology Companies

9.2.1 Market Estimates & Forecast, 2020-2027

9.3 Academic & Government Research Institutes

9.3.1 Market Estimates & Forecast, 2020-2027

9.4 Pharmaceuticals

9.4.1 Market Estimates & Forecast, 2020-2027

9.5 Others

Chapter .8 Global Recombinant DNA Technology Market, by Region

8.1 Introduction

8.2 Americas

8.2.1 North America

8.2.1.1 U.S.

8.2.1.1 Canada

8.2.2 South America

8.3 Europe

8.3.1 Western Europe

8.3.1.1 Germany

8.3.1.2 France

8.3.1.3 Italy

8.3.1.4 Spain

8.3.1.5 U.K.

8.3.1.6 Rest of Western Europe

8.3.2 Eastern Europe

8.4 Asia Pacific

8.4.1 Japan

8.4.2 China

8.4.3 India

8.4.4 Australia

8.4.5 Republic of Korea

8.4.6 Rest of Asia Pacific

8.5 The Middle East & Africa

8.5.1 United Arab Emirates

8.5.2 Saudi Arabia

8.5.3 Oman

8.5.4 Kuwait

8.5.5 Qatar

8.5.6 Rest of the Middle East & Africa

Chapter 9 Company Landscape

9.1 Introduction

9.2 Market Share Analysis

9.3 Key Development & Strategies

9.3.1 Key Developments

Chapter 10 Company Profiles

10.1 F. Hoffmann-La Roche Ltd

10.1.1 Company Overview

10.1.2 Product Overview

10.1.3 Financials

10.1.4 SWOT Analysis

10.2 Profacgen

10.2.1 Company Overview

10.2.2 Product Overview

10.2.3 Financial Overview

10.2.4 Key Developments

10.2.5 SWOT Analysis

10.3 Amgen Inc.

10.3.1 Company Overview

10.3.2 Product Overview

10.3.3 Financial Overview

10.3.4 Key Development

10.3.5 SWOT Analysis

10.4 Novartis AG

10.4.1 Company Overview

10.4.2 Product/Business Segment Overview

10.4.3 Financial Overview

10.4.4 Key Development

10.4.5 SWOT Analysis

10.5 Genscript Biotech

10.5.1 Company Overview

10.5.2 Product Overview

10.5.3 Financial overview

10.5.4 Key Developments

10.6 Pfizer Inc.

10.6.1 Company Overview

10.6.2 Product Overview

10.6.3 Financial Overview

10.6.4 Key Developments

10.7 Novo Nordisk A/S

10.7.1 Overview

10.7.2 Product Overview

10.7.3 Financials

10.7.4 Key Developments

10.7.5 SWOT Analysis

10.8 Eli Lilly and Company

10.8.1 Company Overview

10.8.2 Product/Business Segment Overview

10.8.3 Financial Overview

10.8.4 Key Development

10.8.5 SWOT Analysis

10.9 Sanofi S.A.

10.9.1 Company Overview

10.9.2 Product Overview

10.9.3 Financial overview

10.9.4 Key Developments

10.10 Merck & Co., Inc.

10.10.1 Company Overview

10.10.2 Product Overview

10.10.3 Financial overview

10.10.4 Key Developments

10.11 Biogen Inc.

10.11.1 Company Overview

10.11.2 Product Overview

10.11.3 Financial overview

10.11.4 Key Developments

10.12 Others

Chapter 17 MRFR Conclusion

11.1 Key Findings

11.1.1 From CEO’s View Point

11.1.2 Unmet Needs of the Market

11.2 Key Companies to Watch

11.3 Prediction of the Pharmaceutical Industry

Chapter 12 Appendix

LIST OF TABLES

Table 1 Recombinant DNA technology Industry Synopsis, 2020-2027

Table 2 Recombinant DNA Technology Market Estimates & Forecast, 2020-2027, (USD Million)

Table 3 Recombinant DNA Technology Market, by Region, 2020-2027, (USD Million)

Table 4 Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)

Table 5 Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)

Table 6 Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)

Table 7 Recombinant DNA Technology Market, by End-U.S.er, 2020-2027, (USD Million)

Table 8 North America Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)

Table 9 North America Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)

Table 10 North America Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)

Table 11 North America Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)

Table 12 U.S. Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)

Table 13 U.S. Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)

Table 14 U.S. Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)

Table 15 U.S. Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)

Table 16 Canada Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)

Table 17 Canada Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)

Table 18 Canada Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)

Table 19 Canada Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)

Table 20 South America Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)

Table 21 South America Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)

Table 22 South America Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)

Table 23 South America Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)

Table 24 Europe Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)

Table 25 Europe Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)

Table 26 Europe Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)

Table 27 Europe Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)

Table 28 Western Europe Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)

Table 29 Western Europe Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)

Table 30 Western Europe Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)

Table 31 Western Europe Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)

Table 32 Eastern Europe Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)

Table 33 Eastern Europe Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)

Table 34 Eastern Europe Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)

Table 35 Eastern Europe Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)

Table 36 Asia Pacific Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)

Table 37 Asia Pacific Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)

Table 38 Asia Pacific Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)

Table 39 Asia Pacific Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)

Table 40 The Middle East & Africa Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)

Table 41 The Middle East & Africa Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)

Table 42 The Middle East & Africa Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)

Table 43 The Middle East & Africa Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation of the Recombinant DNA Technology Market

Figure 3 Segmentation Market Dynamics for the Recombinant DNA Technology Market

Figure 4 Global Recombinant DNA Technology Market Share, by Product 2020

Figure 5 Global Recombinant DNA Technology Market Share, by Component 2020

Figure 6 Global Recombinant DNA Technology Market Share, by Application 2020

Figure 7 Global Recombinant DNA Technology Market Share, by End-User2020

Figure 8 Global Recombinant DNA Technology Market Share, by Region, 2020

Figure 9 Americas Recombinant DNA Technology Market Share, by Country, 2020

Figure 10 Europe Recombinant DNA Technology Market Share, by Country, 2020

Figure 11 Asia Pacific Recombinant DNA Technology Market Share, by Country, 2020

Figure 12 Middle East & Africa Recombinant DNA Technology Market Share, by Country, 2020

Figure 13 Global Recombinant DNA Technology Market: Company Share Analysis, 2020 (%)

Figure 14 F. Hoffmann-La Roche Ltd: Key Financials

Figure 15 F. Hoffmann-La Roche Ltd: Segmental Revenue

Figure 16 F. Hoffmann-La Roche Ltd: Geographical Revenue

Figure 17 Profacgen: Key Financials

Figure 18 Profacgen: Segmental Revenue

Figure 19 Profacgen: Geographical Revenue

Figure 20 Amgen Inc.: Key Financials

Figure 21 Amgen Inc.: Segmental Revenue

Figure 22 Amgen Inc.: Geographical Revenue

Figure 23 Novartis AG: Key Financials

Figure 24 Novartis AG: Segmental Revenue

Figure 25 Novartis AG: Geographical Revenue

Figure 26 Genscript Biotech: Key Financials

Figure 27 Genscript Biotech: Segmental Revenue

Figure 28 Genscript Biotech: Geographical Revenue

Figure 29 Pfizer Inc.: Key Financials

Figure 30 Pfizer Inc.: Segmental Revenue

Figure 31 Pfizer Inc.: Geographical Revenue

Figure 32 Novo Nordisk A/S: Key Financials

Figure 33 Novo Nordisk A/S: Segmental Revenue

Figure 34 Novo Nordisk A/S: Geographical Revenue

Figure 35 Eli Lilly and Company: Key Financials

Figure 36 Eli Lilly and Company: Segmental Revenue

Figure 37 Eli Lilly and Company: Geographical Revenue

Market Segmentation


Recombinant DNA Technology Product Outlook (USD Billion, 2018-2032)




  • Medical




  • Non-Medical




Recombinant DNA Technology Component Outlook (USD Billion, 2018-2032)




  • Expression System




  • Cloning Vector




Recombinant DNA Technology Application Outlook (USD Billion, 2018-2032)




  • Food & Agriculture




  • Health & Disease




Recombinant DNA Technology End User Outlook (USD Billion, 2018-2032)




  • Biotechnology Companies




  • Pharmaceuticals




Recombinant DNA Technology Regional Outlook (USD Billion, 2018-2032)




  • North America Outlook (USD Billion, 2018-2032)




    • North America Recombinant DNA Technology by Product




      • Medical




      • Non-Medical






    • North America Recombinant DNA Technology by Component




      • Expression System




      • Cloning Vector






    • North America Recombinant DNA Technology by Application




      • Food & Agriculture




      • Health & Disease






    • North America Recombinant DNA Technology by End User




      • Biotechnology Companies




      • Pharmaceuticals






    • US Outlook (USD Billion, 2018-2032)




    • US Recombinant DNA Technology by Product




      • Medical




      • Non-Medical






    • US Recombinant DNA Technology by Component




      • Expression System




      • Cloning Vector






    • US Recombinant DNA Technology by Application




      • Food & Agriculture




      • Health & Disease






    • US Recombinant DNA Technology by End User




      • Biotechnology Companies




      • Pharmaceuticals






    • CANADA Outlook (USD Billion, 2018-2032)




    • CANADA Recombinant DNA Technology by Product




      • Medical




      • Non-Medical






    • CANADA Recombinant DNA Technology by Component




      • Expression System




      • Cloning Vector






    • CANADA Recombinant DNA Technology by Application




      • Food & Agriculture




      • Health & Disease






    • CANADA Recombinant DNA Technology by End User




      • Biotechnology Companies




      • Pharmaceuticals








  • Europe Outlook (USD Billion, 2018-2032)




    • Europe Recombinant DNA Technology by Product




      • Medical




      • Non-Medical






    • Europe Recombinant DNA Technology by Component




      • Expression System




      • Cloning Vector






    • Europe Recombinant DNA Technology by Application




      • Food & Agriculture




      • Health & Disease






    • Europe Recombinant DNA Technology by End User




      • Biotechnology Companies




      • Pharmaceuticals






    • Germany Outlook (USD Billion, 2018-2032)




    • Germany Recombinant DNA Technology by Product




      • Medical




      • Non-Medical






    • Germany Recombinant DNA Technology by Component




      • Expression System




      • Cloning Vector






    • Germany Recombinant DNA Technology by Application




      • Food & Agriculture




      • Health & Disease






    • Germany Recombinant DNA Technology by End User




      • Biotechnology Companies




      • Pharmaceuticals






    • France Outlook (USD Billion, 2018-2032)




    • France Recombinant DNA Technology by Product




      • Medical




      • Non-Medical






    • France Recombinant DNA Technology by Component




      • Expression System




      • Cloning Vector






    • France Recombinant DNA Technology by Application




      • Food & Agriculture




      • Health & Disease






    • France Recombinant DNA Technology by End User




      • Biotechnology Companies




      • Pharmaceuticals






    • UK Outlook (USD Billion, 2018-2032)




    • UK Recombinant DNA Technology by Product




      • Medical




      • Non-Medical






    • UK Recombinant DNA Technology by Component




      • Expression System




      • Cloning Vector






    • UK Recombinant DNA Technology by Application




      • Food & Agriculture




      • Health & Disease






    • UK Recombinant DNA Technology by End User




      • Biotechnology Companies




      • Pharmaceuticals






    • ITALY Outlook (USD Billion, 2018-2032)




    • ITALY Recombinant DNA Technology by Product




      • Medical




      • Non-Medical






    • ITALY Recombinant DNA Technology by Component




      • Expression System




      • Cloning Vector






    • ITALY Recombinant DNA Technology by Application




      • Food & Agriculture




      • Health & Disease






    • ITALY Recombinant DNA Technology by End User




      • Biotechnology Companies




      • Pharmaceuticals






    • SPAIN Outlook (USD Billion, 2018-2032)




    • Spain Recombinant DNA Technology by Product




      • Medical




      • Non-Medical






    • Spain Recombinant DNA Technology by Component




      • Expression System




      • Cloning Vector






    • Spain Recombinant DNA Technology by Application




      • Food & Agriculture




      • Health & Disease






    • Spain Recombinant DNA Technology by End User




      • Biotechnology Companies




      • Pharmaceuticals






    • Rest Of Europe Outlook (USD Billion, 2018-2032)




    • Rest Of Europe Recombinant DNA Technology by Product




      • Medical




      • Non-Medical






    • Rest Of Europe Recombinant DNA Technology by Component




      • Expression System




      • Cloning Vector






    • Rest Of Europe Recombinant DNA Technology by Application




      • Food & Agriculture




      • Health & Disease






    • Rest Of Europe Recombinant DNA Technology by End User




      • Biotechnology Companies




      • Pharmaceuticals








  • Asia-Pacific Outlook (USD Billion, 2018-2032)




    • Asia-Pacific Recombinant DNA Technology by Product




      • Medical




      • Non-Medical






    • Asia-Pacific Recombinant DNA Technology by Component




      • Expression System




      • Cloning Vector






    • Asia-Pacific Recombinant DNA Technology by Application




      • Food & Agriculture




      • Health & Disease






    • Asia-Pacific Recombinant DNA Technology by End User




      • Biotechnology Companies




      • Pharmaceuticals






    • China Outlook (USD Billion, 2018-2032)




    • China Recombinant DNA Technology by Product




      • Medical




      • Non-Medical






    • China Recombinant DNA Technology by Component




      • Expression System




      • Cloning Vector






    • China Recombinant DNA Technology by Application




      • Food & Agriculture




      • Health & Disease






    • China Recombinant DNA Technology by End User




      • Biotechnology Companies




      • Pharmaceuticals






    • Japan Outlook (USD Billion, 2018-2032)




    • Japan Recombinant DNA Technology by Product




      • Medical




      • Non-Medical






    • Japan Recombinant DNA Technology by Component




      • Expression System




      • Cloning Vector






    • Japan Recombinant DNA Technology by Application




      • Food & Agriculture




      • Health & Disease






    • Japan Recombinant DNA Technology by End User




      • Biotechnology Companies




      • Pharmaceuticals






    • India Outlook (USD Billion, 2018-2032)




    • India Recombinant DNA Technology by Product




      • Medical




      • Non-Medical






    • India Recombinant DNA Technology by Component




      • Expression System




      • Cloning Vector






    • India Recombinant DNA Technology by Application




      • Food & Agriculture




      • Health & Disease






    • India Recombinant DNA Technology by End User




      • Biotechnology Companies




      • Pharmaceuticals






    • Australia Outlook (USD Billion, 2018-2032)




    • Australia Recombinant DNA Technology by Product




      • Medical




      • Non-Medical






    • Australia Recombinant DNA Technology by Component




      • Expression System




      • Cloning Vector






    • Australia Recombinant DNA Technology by Application




      • Food & Agriculture




      • Health & Disease






    • Australia Recombinant DNA Technology by End User




      • Biotechnology Companies




      • Pharmaceuticals






    • Rest of Asia-Pacific Outlook (USD Billion, 2018-2032)




    • Rest of Asia-Pacific Recombinant DNA Technology by Product




      • Medical




      • Non-Medical






    • Rest of Asia-Pacific Recombinant DNA Technology by Component




      • Expression System




      • Cloning Vector






    • Rest of Asia-Pacific Recombinant DNA Technology by Application




      • Food & Agriculture




      • Health & Disease






    • Rest of Asia-Pacific Recombinant DNA Technology by End User




      • Biotechnology Companies




      • Pharmaceuticals








  • Rest of the World Outlook (USD Billion, 2018-2032)




    • Rest of the World Recombinant DNA Technology by Product




      • Medical




      • Non-Medical






    • Rest of the World Recombinant DNA Technology by Component




      • Expression System




      • Cloning Vector






    • Rest of the World Recombinant DNA Technology by Application




      • Food & Agriculture




      • Health & Disease






    • Rest of the World Recombinant DNA Technology by End User




      • Biotechnology Companies




      • Pharmaceuticals






    • Middle East Outlook (USD Billion, 2018-2032)




    • Middle East Recombinant DNA Technology by Product




      • Medical




      • Non-Medical






    • Middle East Recombinant DNA Technology by Component




      • Expression System




      • Cloning Vector






    • Middle East Recombinant DNA Technology by Application




      • Food & Agriculture




      • Health & Disease






    • Middle East Recombinant DNA Technology by End User




      • Biotechnology Companies




      • Pharmaceuticals






    • Africa Outlook (USD Billion, 2018-2032)




    • Africa Recombinant DNA Technology by Product




      • Medical




      • Non-Medical






    • Africa Recombinant DNA Technology by Component




      • Expression System




      • Cloning Vector






    • Africa Recombinant DNA Technology by Application




      • Food & Agriculture




      • Health & Disease






    • Africa Recombinant DNA Technology by End User




      • Biotechnology Companies




      • Pharmaceuticals






    • Latin America Outlook (USD Billion, 2018-2032)




    • Latin America Recombinant DNA Technology by Product




      • Medical




      • Non-Medical






    • Latin America Recombinant DNA Technology by Component




      • Expression System




      • Cloning Vector






    • Latin America Recombinant DNA Technology by Application




      • Food & Agriculture




      • Health & Disease






    • Latin America Recombinant DNA Technology by End User




      • Biotechnology Companies




      • Pharmaceuticals







Leading companies partner with us for data-driven Insights.
Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response
Invalid